Slingshot members are tracking this corporate initiative:
AbbVie and Bristol-Myers Squibb Announce Oncology Clinical Collaboration to Evaluate the Combination of Rova-T plus Opdivo and Opdivo + Yervoy Regimen
Do you think this event is important to the companies below? How will it affect their stock price?
The Phase 1/2 clinical program will explore the potential of combining Bristol-Myers Squibb’s immuno-oncology agents, which are designed to alleviate immune suppression, in conjunction with AbbVie’s investigational antibody drug conjugate, Rova-T, to drive improved and sustained efficacy and tolerability above the current standard of care. Rova-T is a novel antibody drug conjugate that targets and eliminates tumor initiating cells and other bulk tumor cells. This collaboration will determine if the targeted cell killing and antigen release caused by Rova-T may further enhance the effect of immunotherapy.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Jul 25, 2016 Projected Implementation: Q3, 2016 Relevance Tracked Until: Q4, 2016
Don’t see a project related to the strategic initiative you care about?
Related Keywords Opdivo, Yervoy, Rova-t, Collaboration, Ipilimumab, Sclc, Antibody Drug Conjugate